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ABSTRACT:
Folate receptor alpha (FRA) is a cell surface protein whose aberrant expression 
in malignant cells has resulted in its pursuit as a therapeutic target and marker 
for diagnosis of cancer. The development of immune-based reagents that can 
reproducibly detect FRA from patient tissue processed by varying methods 
has  been  difficult due  to the complex post-translational structure  of the protein 
whereby most reagents developed to date are highly structure-sensitive and have 
resulted in equivocal expression results across independent studies. The aim 
of the present study was to generate novel monoclonal antibodies (mAbs) using 
modified full length FRA protein as immunogen in order to develop a panel of mAbs 
to various, non-overlapping epitopes that may serve as diagnostic reagents able 
to robustly detect FRA-positive disease. Here we report the development of a 
panel of FRA-specific mAbs that are able to specifically detect FRA using an array 
of diagnostic platforms and methods. In addition, the methods used to develop 
these mAbs and their diverse binding properties provide additional information 
on the three dimensional structure of FRA in its native cell surface configuration.
INTRODUCTION
Folate receptor alpha (FRA) is a 
glycosylphosphatidylinositol (GPI) anchored cell surface 
glycoprotein that is able to bind free folate with high 
affinity [1]. It is a member of a family of proteins whose 
function is the management of folate transport in cells. 
FRA  is  distinct  from  the  more  ubiquitously  expressed 
reduced folate carrier (RFC) or the intestine-localized 
proton coupled folate transporter (PCFT) proteins, as 
these are both membrane-spanning receptors that facilitate 
bidirectional transport of reduced folate across the plasma 
and endosomal membranes [2]. 
FRA  is  a  member  of  a  family  of  folate  binding 
receptors that have diverse structural identities but 
mediate  unidirectional  transport  of  folates  into  cells. 
Four isoforms of this receptor family have been identified 
and are designated as folate receptor alpha (FRA), beta 
(FRB), delta (FRD) and gamma (FRG), respectively. The 
FRA and FRB isoforms are both GPI-anchored proteins 
with two N-glycosylation sites and have high affinity (KD 
~1 nM) for folic acid/vitamin B9 [3]. These two family 
members share the highest identity among this protein 
family. It is postulated that these receptors function as 
folate scavengers when folate supply is low or rapid cell 
growth requires elevated uptake of folate for methylation 
reactions  including  DNA  biosynthesis.  The  expression 
of FRA and FRB are distinct in normal and malignant 
tissues. In normal tissue, FRA is mainly expressed on 
the apical surface of a subset of polarized epithelial cells Oncotarget 2011; 2:   1227 - 1243 1228 www.impactjournals.com/oncotarget
whereas  its  aberrant  expression  has  been  prominently 
correlated with malignancies of epithelial origin [4]. FRB 
has  been  found  to  be  mostly  limited  to  hematopoietic 
cells of the myelogenous lineage [5]. Table 1 compares 
and contrasts the properties of the ubiquitous RFC and the 
tissue-specific FRA and FRB proteins.
FRA is the most widely studied folate receptor from 
this  family  due  to  its  restricted  expression  in  normal 
tissues and high expression patterns in various epithelial 
derived tumors [6]. FRA expression and association with 
malignant cells was further supported by tumor antigen 
discovery studies using human tumor cells in immune-
competent  mice  in  an  unbiased  effort  to  identify  cell 
surface  tumor  antigens  via  humoral  immune  responses 
to proteins expressed by tumor cells [7]. These efforts 
led to the discovery of an antibody called LK26, whose 
tumor specific binding to fresh frozen malignant tissues 
using  immunohistochemistry  (IHC)  led  to  the  pursuit 
and isolation of the antigen that in turn was identified 
to be FRA. A humanized version of the LK26 antibody 
was subsequently generated and found to have identical 
binding properties to the LK26 precursor. This humanized 
form is called MORAb-003 as well as the generic name, 
farletuzumab. 
Since its discovery, several tumor association studies 
have  been  conducted  using  FRA  specific  antibodies 
that are able to recognize the receptor in the native but 
not  denatured  state,  including  the  LK26  mAb.  Protein 
expression studies have demonstrated FRA to be highly 
and  uniformly  present  in  non-mucinous  carcinomas  of 
the  ovary  and  endometrium,  while  its  expression  was 
also found in other epithelial tumors including non-small 
cell  lung  adenocarcinoma  (NSCLC),  clear  cell  renal 
carcinoma, primary and metastatic colorectal carcinoma 
and  breast  carcinoma  at  lesser  frequencies  [8,  9,  10, 
11]. In ovarian cancer, several reports have found that 
FRA expression increases with tumor stage [12], and is 
associated with decreased survival [13]. 
The FRA pathway has been deemed to be oncogenic 
in nature, based on its high correlation with malignant 
tissues in patients as well as from experimental studies 
conducted by independent laboratories. In vitro studies 
have  found  that  ectopic  over-expression  of  FRA  in 
normal cells can result in cellular transformation that can 
be reversed by suppressing its expression. Other studies 
have shown that inhibition of FRA expression in naturally 
expressing FRA positive tumor cell lines also suppresses 
cellular proliferation [14, 15, 16]. In vivo studies using 
human FRA-expressing tumor xenografts in mice have 
confirmed the ability to suppress tumor growth using anti-
FRA mAbs that can perturb its biological activity [17]. 
The mechanism by which FRA supports tumorigenesis 
is still unclear. While it is possible that recruitment of 
more folate to cells is a mechanism for tumorigenesis, it is 
important to consider other mechanisms as well. Isolation 
of FRA from the membrane of ovarian cancer cells has 
demonstrated  it  to  be  associated  with  several  signal 
transduction molecules that in turn may be involved in 
signaling for enhanced growth [18]. Efforts are underway 
to further elucidate the mechanism by which FRA supports 
tumor cell growth. Despite the lack of understanding of 
the  entire  mechanism  by  which  FRA  supports  cellular 
transformation  and  tumor  cell  growth,  the  association 
of the protein with specific cancer subtypes, as well as 
the  independent  experimental  studies  described  above, 
strongly support a role for FRA and its pathway in cancer 
as a bonafide candidate for targeted cancer therapy [19].
Significant activity in the drug development arena 
is focused on targeting FRA based on its’ highly tumor 
restricted expression profile. Several agents are currently 
in late-stage clinical development that target FRA itself, 
or use the folate binding activity of FRA to deliver folate-
conjugated  toxins.  While  FRA  expression  has  been 
reported to be highly correlated with certain cancers such 
as ovarian and endometrial, patient pre-selection in cancers 
where the frequency of expression is less than ubiquitous 
is important to determine those who may benefit from 
FRA mediated therapy [20, 21, 22]. Unfortunately, due to 
Table 1: Selected Properties of the FRA, FRB and RFC proteins
Characteristic FRA FRB RFC
Protein Structure Single chain/GPI linked Single chain/GPI linked Single unit/ transmembrane
Molecular weight [25, 26] 38kDa 34kDa 60kDa
Cellular Distribution Restricted to epithelial cells Restricted to lymphoid cells Ubiquitous
Folate binding properties:
Folic acid Yes Yes No
5-methyltetrahydrofolate Yes Yes Yes
Anti-folates Yes Yes Yes
Binding affinity for folic 
acid [27]
1 nM 1nM 200-400μM
Binding affinity for 5-
methyl-THF and other 
reduced folates[25]
1–10 nM 1-10nM 1–10μMOncotarget 2011; 2:   1227 - 1243 1229 www.impactjournals.com/oncotarget
the complex secondary structure of the FRA protein, the 
development of reagents that can detect the protein with 
reproducible specificity and high sensitivity is required 
to support the accurate diagnosis of patients with FRA 
positive cancers. In light of the differences in reagents and 
methods used for tissue procurement, varying frequencies 
of expression of FRA in one of the most homogenously 
expressing  cancers,  ovarian  carcinoma,  have  been 
reported,  further  supporting  the  need  for  development 
of more robust diagnostic reagents [23, 24]. Given these 
needs, we embarked on a program to develop specific 
reagents  that  may  prove  useful  for  the  sensitive  and 
specific detection of FRA in tissue or in biological fluids 
such as serum, plasma, urine or sputum. Here we describe 
the  development  of  novel,  high-affinity  mAbs  that  are 
FRA specific and can be applied to multiple diagnostic 
platforms. Moreover, due to the highly complex structure 
of the FRA protein, the analysis of the receptor using the 
reagents described herein has led to the further refinement 
of the three dimensional architecture of this protein. These 
efforts may aid in elucidating the function of how FRA 
supports tumorigenesis.
Antibody
Immunogen Used to 
Develop mAb
IgG
isotype
IHC Reactivity
FFPE (+/-)
FACS Analysis+ on FR 
Expressing Cell Types Reduced WB 
Reactivity (+/-)
FRA FRB FRD
9F3 rFRA IgG2a (-) 760 6 5 (-)
24F12 dFRA IgG1 NT* 777 6 6 (-)
26B3 dFRA IgG1 (+) 854 6 6 (-)
19D4 dFRA IgG2a (+) 1130 NT NT (-)
*NT = Not Tested; +values represent fluorescence intensity
rFRA = full length recombinant human folatereceptor alpha
dFRA = full length denatured, reduced and alkylated human folate receptor alpha
Table 2: Summary Characteristics of Selected mAbs
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Figure 1: Fluorescence Activated Cell Sorting (FACS). Antibodies were tested for their ability to detect FRA on recombinant 
CHO cells expressing human FRA, FRB or FRD. Twenty of the 69 mAbs developed here were able to specifically recognize FRA and not 
the other folate receptor orthologs or negative controls. Shown is a representative analysis of lead antibodies and their robust FRA-specific 
binding. We then tested the ability of these antibodies to cross react to epitopes or with the previously reported anti-FRA mAb MORAb-003 
which is being pursued in clinical development for the treatment of ovarian cancer [20]. Very few mAbs were found to compete for binding. 
Of particular note was the cross reactivity of 24F12 with 26B3 and 19D4 with MORAb-003 (not shown).Oncotarget 2011; 2:   1227 - 1243 1230 www.impactjournals.com/oncotarget
RESULTS
In the present work, two different immunogens were 
used in an attempt to generate FRA specific mAbs; a full 
length recombinant human FRA (rFRA) and a full length 
denatured FRA (dFRA) obtained by urea denaturation 
followed by reduction and alkylation. FRA is a disulfide 
linked  protein,  containing  seven  disulfides  and,  based 
on similarities to the chicken riboflavin-binding protein 
(cRBP) and the X-ray structure thereof, is thought to be a 
highly compact structure [25]. Based on this structure, it is 
expected that only a limited number of possible epitopes 
are present in the native protein that may be recognized 
by the immune system. In order to expand the number 
of possible epitopes, we generated the dFRA with the 
expectation that it would be less structurally constrained 
and  more  linear  in  nature.  This  immunogen  would 
potentially  have  an  increase  in  the  number  of  distinct 
residues that could yield a broad panel of novel antibodies 
that may be useful in the robust and reproducible detection 
of  FRA  in  tissues  processed  by  a  variety  of  methods, 
other biological samples such as serum, as well as being 
useful in providing additional information about the three 
dimensional structure of FRA.
The  immunizations  using  rFRA  and  the  dFRA 
produced strikingly different responses whereby a total 
of  7  and  62  parental  anti-FRA  producing  hybridoma 
lines  were  generated,  respectively.  These  differences 
are  most  likely  due  to  the  immunogen  structure  since 
the  procedure  for  immunization  of  both  antigens,  and 
screening of clones, were conducted using identical 
methods. These data imply that disruption of the tertiary 
structure of FRA, by reduction of the disulfides followed 
by alkylation of the cysteines, significantly improves its 
immunogenicity and suggests that this procedure might 
be useful for developing broad panels of mAbs to other 
high disulfide-rich proteins as well. One possible reason 
for the low number of anti-FRA antibodies derived from 
rFRA immunization is the high degree of homology that 
may exist between the native human and mouse proteins 
that resulted in tolerance to the rFRA protein in the murine 
host.  Conversely,  the  dFRA  may  have  more  exposed 
epitopes and unmasked non-conserved sequences/domains 
between the two species. Analysis of the mouse and human 
FRA proteins demonstrates that an 81% identity exists at 
the primary amino acid sequence level, whereas folding 
and external surface exposure of conserved regions may 
result in higher similarities between the two species [28]. 
Further characterization of the antibodies generated using 
both immunogens found that most of those obtained from 
the rFRA immunizations were of relatively low affinity 
as  determined  by  BIAcore  analysis,  further  supporting 
the hypothesis that the native human and mouse proteins 
share a high degree of homology on the external surfaces 
of  the  native  proteins.  Of  the  seven  rFRA-derived 
antibodies, only one (9F3), proved to be suitable for FRA 
recognition using the battery of assays described below 
while the majority of dFRA-derived antibodies had high 
affinity and robust FRA binding (Table 2). Interesting is 
the fact that the EIA assay used to screen for anti-FRA 
antibodies  from  both  immunogens  employed  the  non-
denatured  rFRA  thereby  demonstrating  the  ability  of 
these antibodies to presumably recognize epitopes present 
in FRA in the native state. To better characterize these 
antibodies, twenty of the best binders as scored by EIA 
were further analyzed for FRA binding using a variety of 
assays including FACS and IHC of positive and negative 
FRA expressing tissues.
FACS analysis of the lead antibodies using 
recombinant CHO cell lines expressing the human FRA, 
or the orthologs FRB and FRD, was conducted to test for 
binding specificity. Results of these studies found that all 
20 antibodies were able to specifically bind CHO-FRA but 
not cells expressing the FRB or FRD orthologs. Results 
depicting the FACS binding for a subset of these antibodies 
are  shown  in  Figure  1.  Competition  studies  were  also 
performed on these cells using various combinations of 
antibodies to determine if any of the mAbs competed with 
each other for FRA binding. As expected a number of 
antibodies appeared to compete with each other for FRA 
binding  and  only  one  competitive  antibody  from  each 
group was further assessed for binding in epitope mapping 
studies  described  below.  The  LK26  antibody  that  was 
originally developed using a whole tumor immunization 
protocol was used as a positive control to confirm FRA 
expression  and  mAb  specific  binding  [7].  Competition 
studies using the new mAbs generated here found that 
only one, 19D4, was able to compete for binding of LK26, 
suggesting overlapping epitopes or perturbation of the 
LK26 epitope by 19D4. 
We  next  tested  the  ability  of  the  antibodies  to 
bind rFRA or FRA from recombinant CHO cell lysates 
expressing  FRA  and  other  orthologs  ectopically  via 
western blots under reduced and non-reduced conditions. 
Figure 2 shows a representative analysis of the ability of 
these antibodies to recognize FRA under both conditions. 
The FRB, FRD and FRG orthologs were included as 
controls to test for binding specificity. The LK26 and BN.3 
antibodies that recognize FRA under denatured and non-
reduced or reduced only conditions were used as positive 
controls,  respectively  [7,  29].  Nineteen  of  the  twenty 
mAbs tested were able to robustly detect FRA when run 
under denatured and non-reduced conditions while no 
cross reactivity to FRB, FRD or FRG was observed for any 
antibody. This result is somewhat surprising in light of the 
fact that all of the antibodies except for 9F3, which only 
weakly  recognized  non-reduced  FRA  under  denatured 
conditions, were derived from immunizations using the 
dFRA preparation but may reflect the stringent screening 
process employed in the present work. These data further 
demonstrate that while most of these antibodies recognize 
linear epitopes (as determined by reactivity on denatured Oncotarget 2011; 2:   1227 - 1243 1231 www.impactjournals.com/oncotarget
non-reduced western blots) a subset of them recognize 
conformational or constrained epitopes as determined by 
their inability to react with FRA on reduced western blots. 
This data would suggest conformation-specific epitopes 
for several of these antibodies and their epitopes could 
provide  insight  into  the  three  dimensional  structure  of 
the native FRA protein. Indeed, H/D exchange epitope 
mapping of several of these antibodies suggest non-linear 
epitopes and/or epitopes that are flanked by cysteines that 
likely provide secondary structure (see below).
When  performing  immunohistochemistry  (IHC) 
to  probe  for  antigen  expression  in  FFPE  (Formalin 
Fixed  Paraffin  Embedded)  processed  tissue  samples, 
antibodies typically recognize a linear epitope devoid of 
tertiary structure due to the harsh denaturing that occurs 
during fixation and the often incomplete antigen retrieval 
process.  As  such,  antibodies  for  IHC  applications  are 
most often selected based on their ability to recognize 
antigen on reduced western blots. Several of the current 
mAbs  tested  here,  in  particular  clone  26B3,  do  not 
appear to fit this model and are therefore rather unique. 
This was demonstrated using FFPE sections of various 
normal and malignant tissues including papillary serous 
ovarian cancer for which FRA expression has been highly 
correlated  independent  of  the  type  of  immunological 
method or reagent used. Parallel analysis of the antibodies 
developed here demonstrated that the 26B3 antibody had 
the  most  robust  binding  to  FRA  positive  tissues  using 
either FFPE or FF preparations while tissues previously 
confirmed to be negative for FRA by IHC using other 
monoclonal and polyclonal antibodies or mRNA analysis 
were negative (Figure 3).
These  mAbs  were  next  tested  on  normal  tissues 
from  organs  previously  found  to  express  FRA  on  the 
luminal surface (kidney, salivary gland, alveolar surface 
of  the  lung,  etc.)  and  negative  for  FRA  (ovary,  liver, 
heart, etc.) as well as previously reported FRA-positive 
carcinomas (ovarian, NSCLC, renal, breast, etc.). All of 
the antibodies were found to show concordant staining in 
the positive or negative tissues as expected. Interestingly, 
the 26B3 antibody recognizes FRA by FACS and western 
blot under non-reduced conditions but not under reduced 
conditions. Yet, when used for IHC, the antibody is able 
to recognize FRA in FFPE tissues as shown in Figure 3. 
Previous studies using other anti-FRA antibodies such 
as  LK26,  Mov18  and  Mov19  have  found  that  these 
antibodies can recognize FRA in tissues prepared by 
FF methods only and not on FFPE tissue sections (30, 
authors, unpublished observations). This may be partly 
due to the antigen structure and its stability using various 
tissue  fixation  techniques.  However,  FRA  stability  to 
fixation cannot be the sole explanation since only the 9F3 
Figure 2: Western blotting of mAbs to reduced and non-reduced FR isoforms. Purified recombinant (panel A) and whole cell 
lysates (panel B) from CHO cells expressing FRA or FR homologs FRB, FRD or FRG were run on SDS-PAGE gels. Proteins were prepared 
in sample buffer with or without reducing agents. Panel A, lane 1, molecular weight markers, lanes 2-5. 0.5µg reduced FRA, FRB, FRG, 
and FRD, respectively; lane 6, blank; lanes 7-10, 0.5µg non-reduced FRA, FRB, FRG, and FRD, respectively. The positive band represents 
the only reactive species in each lane and corresponds to a molecular weight of ~38kDa. Panel B, lane 1 molecular weight markers, lane 
2 CHO-FRA, lane 3, CHO-FRB, lane 4 CHO-FRD whole cell lysates prepared in sample buffer without reducing agents on a SDS-PAGE 
gel. Each panel is probed with the designated anti-FRA mAb labeled on the right. The molecular weights for FR are: FRA ~38kDA; FRB 
~30kDa; FRG ~28kDa; FRD ~26kDa.Oncotarget 2011; 2:   1227 - 1243 1232 www.impactjournals.com/oncotarget
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Figure 3: IHC of mAbs on human tissues. mAbs were used to assess the ability to detect FRA in tissues prepared via FFPE or FF 
methods. Shown is a representative analysis of anti-FRA mAbs developed here that demonstrate specific staining of FRA positive tissues 
prepared using various methods. mAb 26B3 showed the most robust staining for FRA in IHC and is presented above. Shown is the ability of 
26B3 to detect FRA in normal tissues and previously identified FRA-positive cancers (serous ovarian cancer and NSCLC adenocarcinoma) 
prepared using formalin fixed paraffin embedded (FFPE, right column) and fresh frozen (FF, left column) tissue. As shown, mAb 26B3 is 
able to robustly recognize antigen in both tissue preparations. Slides shown at 20X magnification.Oncotarget 2011; 2:   1227 - 1243 1233 www.impactjournals.com/oncotarget
mAb, which had similar binding properties to 26B3 in 
FACS and western blots did not recognize FRA in FFPE. 
One potential reason for the robust binding of mAb 26B3 
to FRA in FFPE tissues is likely due to its high affinity. 
As noted previously, the mAbs described herein generated 
using the dFRA were of very high affinity (see Table 3), 
however, the 26B3 antibody had a distinctly slower off 
rate relative to all of the other mAbs tested which may 
account for its more robust binding. Regardless of reason, 
the reproducible ability to recognize FRA using different 
diagnostic platforms (i.e., EIA, FACS, WB, IHC on FFPE 
or FF tissues, etc) makes mAb 26B3 an ideal candidate for 
further assay development work.
To  further  characterize  the  26B3  and  a  subset  of 
other mAbs derived here, epitope binning studies were 
conducted to more thoroughly identify and confirm those 
that cross compete for FRA binding. This analysis may 
also be useful for gaining additional information on the 
three dimensional FRA protein itself using methods as 
previously described [31]. Two mAbs, 26B3 and 24F12, 
which have high affinities to purified rFRA, competed for 
binding to FRA, while the other antibodies appeared to 
bind distinct and non-overlapping epitopes. mAb 19D4 
appeared to compete with LK26/MORAb-003 for FRA 
binding suggesting an overlap of common epitopes and/
or perturbation of the three dimensional structure of FRA. 
The epitope binning data was confirmed by competitive 
Figure 4: Design of H/D mapping strategy. To map regions of the free FRA protein or protein bound to mAb, the protein is incubated 
with “on solution” that exchanges external hydrogens (depicted by blue circles) with deuterium ions (red circles). Upon saturation, the 
deuterated FRA is then incubated in H2O which exchanges hydrogen for deuterium in unbound regions or regions no longer protected 
by subsequent mAb binding. As control, “on-column” reactions are conducted whereby non-deuterated FRA is bound by mAb and then 
deuterated followed by hydrogen exchange to identify protected region bound by the anti-FRA mAb. To identify external regions on the 
free FRA protein, reactions are conducted with FRA at varying time points. The green circles represent the FRA protein. The yellow 
cylinder represents the anti-FRA antibody binding region which inhibits the hydrogen or deuterium exchange on the deuterated or non-
deuterated FRA protein, respectively.
Figure 5: Hydrogen/deuterium exchange map of the recombinant human folate receptor alpha (rFRA) in solution. 
H/D exchange map of rFRA at 23°C at pH7.0. Each block represents overlapping peptides analyzed. Each block contains 5 time points, as 
indicated on the legend to the right. Deuteration level at each time point on each peptide is indicated on the legend as well. For externally 
exposed regions fast H/D rates at the 30s time point that increase linearly with extended incubation periods indicate more externally 
exposed surfaces [32]. As shown here, amino acid regions 45-57, 129-142 and 174-184 indicate the most externally accessible regions on 
the FRA molecule.
Table 3: Affinity Constants of Selected mAbs
Antibody ka(1/M*s) kd(1/s) KD (M)
26B3 5.24x105 1.43x10-5 2.73x10-11
24F12 3.93x105 3.99x10-5 1.02x10-10
19D4 4.27x105 2.42x10-4 5.67x10-10
9F3 4.34x105 3.10x10-4 7.15x10-10
Affinities were determined using surface 
plasmon resonance on a BIAcore T100 
instrumentOncotarget 2011; 2:   1227 - 1243 1234 www.impactjournals.com/oncotarget
FACS analysis as described above. To further refine the 
binding epitopes of these mAbs as well as the humanized 
LK26  isoform  (MORAb-003)  and  9F3  mAbs,  H/D 
exchange assays were conducted.
H/D-exchange  analyses  of  rFRA  alone  or  rFRA 
bound  with  either  9F3,  24F12,  26B3  or  MORAb-003 
mAbs  were  conducted  as  previously  described  [32]. 
Figure  4  provides  a  summary  of  the  H/D  exchange 
process. After H/D exchange, the external domains of the 
folded FRA protein as well as epitope maps for each of the 
antibodies were determined. The epitope for MORAb-003 
was determined to be located between residues 45 and 57 
(Figure  6A).  This  epitope  was  further  refined  using 
alanine-scanning mutagenesis that demonstrated changes 
in  amino  acids  Ala-His-Lys-Asp  within  this  region 
inhibited  MORAb-003  binding  to  FRA  (Figure  6B). 
Because MORAb-003 binding is limited to non-reduced 
FRA and competition experiments using linear or cyclized 
synthetic peptide corresponding to the region 45-57 failed 
to  compete  MORAb-003  binding,  even  at  very  high 
concentrations, these data suggest that there are additional 
structural  determinants  to  MORAb-003  binding  other 
than  the  linear  sequence.  Using  similar  methods,  H/D 
exchange mapping was conducted for several of the mAbs 
developed in the present work. The epitope region for 9F3 
was determined to be located between amino acids 17-29. 
Interestingly, while antibodies 26B3 and 24F12 appeared 
to compete with each other for FRA binding, their epitopes 
were located at distinct regions on the FRA protein. H/D 
mapping  found  their  epitopes  to  be  located  between 
regions  174-185  and  67-82,  respectively.  This  finding 
suggested that while the epitopes were a minimum of 92 
amino acids apart on the linear protein sequence, in the 
naturally folded protein they appear to be in sufficiently 
close proximity to effect direct or indirect competition for 
FRA binding. A summary of the epitopes is provided in 
Figure 6: H/D mapping of anti-FRA mAb epitopes via hydrogen/deuteration exchange of FRA upon antibody 
complexation. Shown in Panel A are the perturbations of H/D exchange of rFRA upon antibody binding, illustrated as a heat map for 
each antibody. The level of perturbation, as a percentage, is shown in the legend in the lower right. Included above is the H/D exchange 
map of free rFRA in solution for comparison and alignment of the proposed epitope regions of 24F12, 9F3, 26B3 and MORAb-003 mAbs, 
respectively. For MORAb-003, epitopes were confirmed via di-alanine scanning of full length rFRA vs mutant FRA variants which refined 
the epitope for the antibody from the 45-57 region to amino acid residues HKDV (Panel B). The H/D mapped epitope regions for each 
mAb is identified and provided in Table 4. Panel A. H/D exchange map of anti-FRA mAbs on rFRA at varying incubation time points. The 
antibody for each exchange map is shown on the left and the amino acid sequence of FRA is shown on the top. 
Free rFRA
24F12
9F3
26B3
MORAb-003
Free rFRA Free rFRA
24F12
9F3
26B3
MORAb-003
75 S
250 S
750 S
2500S
Antibody
Epitope Region on FRA 
Protein (amino acid 
positions)
26B3 174-185
24F12 67-82
9F3 17-29
MORAb-003 45-57
Table 4: Epitope Regions of FRA Specific mAbs 
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Table 4.
The reagents generated here and methods by which 
they  were  made  provide  valuable  tools  for  detecting 
FRA protein in tissues and cells prepared using various 
standard  methods  employed  by  pathology  labs  as  well 
as techniques such as EIA. Moreover, as we attempt to 
learn more about the structure and function of how FRA 
participates in cellular transformation, a subset of these 
reagents  may  be  useful  in  providing  more  information 
on the three dimensional structure of the protein until the 
crystal structure of the protein and other three dimensional 
modeling studies are successfully conducted. Of particular 
interest are the two antibodies generated against native 
FRA, MORAb-003 and 9F3 which are only able to detect 
non-reduced FRA protein as well as FRA in tissues prepared 
only under FF methods, not in FFPE prepared samples. 
Additionally, the 26B3, 24F12 and 19D4 mAbs provide 
interesting reagents in that they are able to recognize FRA 
under non-reduced conditions but in tissues prepared via 
FFPE as well as FF, again distinguishing the interesting 
conformation of the epitopes to which they bind. These 
reagents have also been demonstrated to be effective in 
measuring FRA in biological fluids such as serum and 
plasma (authors, unpublished data).
DISCUSSION
The  primary  aim  of  the  present  study  was  to 
develop new reagents that could reproducibly detect FRA 
expression, primarily on tissues or in bodily fluids derived 
from cancer patients in an attempt to generate reagents 
suitable for FRA diagnostics and to support FRA-based 
therapies. These efforts, if successful, could potentially 
enable the development of a diagnostic assay that could 
serve as a suitable probe for staging, differentiating and/
or evaluating the antigen in cancer for prognosis. While 
other anti-FRA reagents have been previously developed, 
a high degree of variability in FRA expression profiles 
across various cancers has been observed likely due to the 
platform and methods of sample preparation [7, 29, 30]. 
Here we describe the development of a panel of distinct, 
high affinity mAbs that recognize different regions of the 
FRA protein. Of particular note is the development of 
mAb 26B3 which is able to detect FRA using a number 
of  standard  sample  isolation  and  detection  platforms. 
The robustness of this antibody is likely due to its high 
affinity that is driven by its slow dissociation constant and 
the unique epitope to which it binds. While many of the 
antibodies developed here, as well as in previous studies, 
have been shown to recognize native specific structures, 
none have been able to detect FRA in tissues prepared 
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            M   G  W  S   C  I  I   L  F  L  V   A  T  A   T  G  V 
1  GCCGCCACCA TGGGATGGAG CTGTATCATC CTCTTCTTGG TAGCAACAGC TACAGGTGTC 
  CGGCGGTGGT ACCCTACCTC GACATAGTAG GAGAAGAACC ATCGTTGTCG ATGTCCACAG 
   H  S  R  I   A  W  A   R  T  E   L  L  N  V   C  M  N   A  K  H 
61  CACTCCAGGA TTGCATGGGC CAGGACTGAG CTTCTCAATG TCTGCATGAA CGCCAAGCAC 
  GTGAGGTCCT AACGTACCCG GTCCTGACTC GAAGAGTTAC AGACGTACTT GCGGTTCGTG 
   H  K  E  K   P  G  P   E  D  K   L  H  E  Q   C  R  P   W  R  K 
121  CACAAGGAAA AGCCAGGCCC CGAGGACAAG TTGCATGAGC AGTGTCGACC CTGGAGGAAG 
  GTGTTCCTTT TCGGTCCGGG GCTCCTGTTC AACGTACTCG TCACAGCTGG GACCTCCTTC 
  MUTANT 1      A   A  S  Q   E  A  H  K   D  V  S   Y  L  1.5 
  MUTANT 2      N   A  A  Q   E  A  H  K   D  V  S   Y  L  1.3 
      MUTANT 3      N   T  A  A   E  A  H  K   D  V  S   Y  L  1.4
  MUTANT 4      N   T  S  A   A  A  H  K   D  V  S   Y  L  1.0 
  MUTANT 5      N   T  S  Q   A  G  H  K   D  V  S   Y  L  0.6 
  MUTANT 6      N   T  S  Q   E  G  A  K   D  V  S   Y  L  3.1 
  MUTANT 7      N   T  S  Q   E  A  A  A   D  V  S   Y  L  5.5 
  MUTANT 8      N   T  S  Q   E  A  H  A   A  V  S   Y  L  1.9 
  MUTANT 9      N   T  S  Q   E  A  H  K   A  A  S   Y  L  1.9 
  MUTANT 10      N   T  S  Q   E  A  H  K   D  A  A   Y  L  1.3 
  MUTANT 11      N   T  S  Q   E  A  H  K   D  V  A   A  L  1.3 
  MUTANT 12      N   T  S  Q   E  A  H  K   D  V  S   A  A  1.7 
   N  A  C  C   S  T  N   T  S  Q   E  A  H  K   D  V  S   Y  L  Y 
181  AATGCCTGCT GTTCTACCAA CACCAGCCAG GAAGCCCATA AGGATGTTTC CTACCTATAT 
  TTACGGACGA CAAGATGGTT GTGGTCGGTC CTTCGGGTAT TCCTACAAAG GATGGATATA 
   R  F  N  W   N  H  C   G  E  M   A  P  A  C   K  R  H   F  I  Q 
241  AGATTCAACT GGAACCACTG TGGAGAGATG GCACCTGCCT GCAAACGGCA TTTCATCCAG 
  TCTAAGTTGA CCTTGGTGAC ACCTCTCTAC CGTGGACGGA CGTTTGCCGT AAAGTAGGTC 
   D  T  C  L   Y  E  C   S  P  N   L  G  P  W   I  Q  Q   V  D  Q 
301  GACACCTGCC TCTACGAGTG CTCCCCCAAC TTGGGGCCCT GGATCCAGCA GGTGGATCAG 
  CTGTGGACGG AGATGCTCAC GAGGGGGTTG AACCCCGGGA CCTAGGTCGT CCACCTAGTC 
   S  W  R  K   E  R  V   L  N  V   P  L  C  K   E  D  C   E  Q  W 
361  AGCTGGCGCA AAGAGCGGGT ACTGAACGTG CCCCTGTGCA AAGAGGACTG TGAGCAATGG 
  TCGACCGCGT TTCTCGCCCA TGACTTGCAC GGGGACACGT TTCTCCTGAC ACTCGTTACC 
   W  E  D  C   R  T  S   Y  T  C   K  S  N  W   H  K  G   W  N  W 
421  TGGGAAGATT GTCGCACCTC CTACACCTGC AAGAGCAACT GGCACAAGGG CTGGAACTGG 
  ACCCTTCTAA CAGCGTGGAG GATGTGGACG TTCTCGTTGA CCGTGTTCCC GACCTTGACC 
   T  S  G  F   N  K  C   A  V  G   A  A  C  Q   P  F  H   F  Y  F 
481  ACTTCAGGGT TTAACAAGTG CGCAGTGGGA GCTGCCTGCC AACCTTTCCA TTTCTACTTC 
  TGAAGTCCCA AATTGTTCAC GCGTCACCCT CGACGGACGG TTGGAAAGGT AAAGATGAAG 
   P  T  P  T   V  L  C   N  E  I   W  T  H  S   Y  K  V   S  N  Y 
541  CCCACACCCA CTGTTCTGTG CAATGAAATC TGGACTCACT CCTACAAGGT CAGCAACTAC 
  GGGTGTGGGT GACAAGACAC GTTACTTTAG ACCTGAGTGA GGATGTTCCA GTCGTTGATG 
   S  R  G  S   G  R  C   I  Q  M   W  F  D  P   A  Q  G   N  P  N 
601  AGCCGAGGGA GTGGCCGCTG CATCCAGATG TGGTTCGACC CAGCCCAGGG CAACCCCAAT 
  TCGGCTCCCT CACCGGCGAC GTAGGTCTAC ACCAAGCTGG GTCGGGTCCC GTTGGGGTTA 
   E  E  V  A   R  F  Y   A  A  A   M  S  G  H   H  H  H   H  H  * 
661  GAGGAGGTGG CGAGGTTCTA TGCTGCAGCC ATGAGTGGCC ACCATCACCA TCACCATTAG 
  CTCCTCCACC GCTCCAAGAT ACGACGTCGG TACTCACCGG TGGTAGTGGT AGTGGTAATC 
   * 
721  TGA 
  ACT 
 
Figure 6: H/D mapping of anti-FRA mAb epitopes via hydrogen/deuteration exchange of FRA upon antibody 
complexation. Panel B. Di-alanine scanning of FRA of the MORAb-003 epitope region 45-57 identified via H/D mapping was conducted 
to further refine the epitope of the antibody. MORAb-003 had reduced binding of FRAs containing changes within the HKDV amino acids 
as determined via surface plasmon resonance. Shown are the 12 mutant di-alanine full length FRA mutants and the binding characteristics 
of MORAb-003 to each mutant with values shown on the right. Oncotarget 2011; 2:   1227 - 1243 1236 www.impactjournals.com/oncotarget
by various platforms that include native and denaturing 
fixation  methods.  Interestingly,  the  26B3  mAb  is  able 
to recognize FRA in its native state and denatured form 
likely due to its recognition of an epitope that juxtaposes 
a cysteine residue that retains significant structure of the 
FRA protein in samples prepared using a variety of tissue 
fixation methods. This hypothesis is further supported by 
the finding that the antibody is able to detect FRA in non-
reduced but not in reduced western blots (Figure 2). This 
antibody is now being tested in broad cancer association 
studies in parallel with other previously reported 
antibodies  [33,  34,  35]  to  compare  its  usefulness  as  a 
diagnostic reagent to support patient screening for FRA-
based targeted therapies as well as its use for identifying, 
staging  and/or  predicting  clinical  outcomes  of  patients 
with FRA positive cancers.
Another finding from this study has been the use of 
the panel of mAbs and H/D exchange mapping of the FRA 
protein itself or when bound by one of the mAbs developed 
here to further define the three dimensional structure of 
the FRA protein. The unique binding properties of these 
mAbs  have  enabled  us  to  evaluate  regional  domains 
of the FRA protein as they relate to their positioning 
on the external surface. As the FRA protein is a highly 
compact multi-disulfide linked structure, the positioning 
of its residues on the external regions of the protein in 
the native state has been better defined by analyzing the 
specific binding of the mAb panel to the FRA protein in 
the native and denatured state, followed by their epitope 
mapping. Indeed those residues predicted to be present on 
the exterior of the protein and confirmed via H/D mapping 
of the free FRA protein are recognized by mAbs that bind 
preferentially to the native (LK26, 19D4 and 9F3) but not 
denatured forms of the protein. Evaluating the binding 
characteristics and epitopes of various mAbs generated 
here  along  with  H/D  exchange  mapping  of  the  native 
protein  can  identify  domains  that  are  freely  exposed 
to  the  surface  of  the  molecule  and  potentially  provide 
additional information on the three dimensional structure 
of the protein. As shown in Figure 5, the regions within 
amino acids 96-100, 145-150, and 174-185 appear to be 
freely exposed based on the H/D exchange mapping of 
the free protein. The regions 45-57 and 129-142 appear 
also  to  be  accessible  to  external  exposure  albeit  to  a 
lesser  extent.  These  findings  corroborate  the  predicted 
three dimensional structure of FRA generated by Shen 
et.al. who used molecular modeling of FRA based on the 
conserved chicken riboflavin (cRBP) protein [36]. Figure 
7 shows a highlight of the external surfaces predicted by 
H/D exchange extrapolated onto the cRBP 3-dimentional 
model. These results showed a good correlation between 
the  predicted  external  domains  and  those  identified  by 
the  H/D  exchange  mapping.  The  additional  binding 
characteristics of the lead antibodies developed here have 
further supported the external topography of these regions 
based on the ability of the mAbs to recognize FRA under 
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Figure 7. Modeling of the anti-FRA antibody epitopes on the FRA-related structure, chicken riboflavin-binding protein (cRBP). 
Sequences of cRBP and hFRA were aligned and linear sequences of anti-FRA antibody epitopes as well as external domains of the free 
FRA protein were mapped on cRBP and highlighted on the cRBP 3-D structure. The model is shown from two different angles to depict the 
epitopes for each antibody as well as the free protein analyzed by H/D mapping. As anticipated by the H/D method, those regions showing 
highest H/D exchange are localized to the external regions of the FRA protein.Oncotarget 2011; 2:   1227 - 1243 1237 www.impactjournals.com/oncotarget
reduced and/or non-reduced conditions. The overlay of 
the epitope regions for each mAb on this model enables 
the three dimensional visualization on how these regions 
juxtapose each other and how binding of these mAbs to 
FRA may effect their ability to bind or inhibit binding of 
various mAb pairs on the native protein.
The data presented here describe the development of 
new antibodies that are able to detect FRA using a variety 
of methods. These antibodies and the models used for 
mapping provide additional information about the FRA 
protein and how it may present itself on the cell surface 
[35, 36]. These data are important for further defining 
regions that may be accessible to new targeting entities 
(i.e. antibodies, antibody fragments, peptides, etc.) that 
can deliver novel pharmacologic agents to FRA-positive 
cells.  Moreover,  recent  findings  by  Knutson  et.al  [37] 
have  found  that  the  FRA  protein  has  external  regions 
that may be recognized by the patient’s immune system 
in those exhibiting various FRA-positive malignancies, 
including  breast  and  ovarian  cancer.  The  epitopes 
identified by autoimmune responses may further aid to 
provide additional information on the native structure of 
the protein as well as how FRA may interact with other 
proteins located in the lipid membrane raft as it signals 
to cells for enhanced or sustained growth [18, 38]. The 
antibodies  described  herein  are  now  being  employed 
in large scale analysis of epithelial-based cancers to 
determine if FRA is a useful marker for detecting, staging 
and or determining the prognosis of patients with FRA 
positive cancers. 
MATERIALS AND METHODS
Expression  and  purification  of  Sf9-expressed 
human FRA
A  human  folate  receptor  alpha  (FRA)  sequence, 
containing  a  leader  sequence  optimized  for  Sf9 
bacculovirus expression, an N-terminal histidine (6xhis) 
epitope  tag,  and  the  intact  native  GPI  attachment  site, 
was used to prepare a high-titer bacculovirus vector 
capable of expressing the recombinant human FRA. 1L 
shake flask cultures containing log-phase Sf9 insect cells 
were  infected  with  the  recombinant  bacculovirus  at  a 
multiplicity of infection (MOI) of <1. Cells from 30L of 
culture were harvested and lysed/extracted twice with 1X 
PBS containing 10mM CHAPS. The NaCl concentration 
was  adjusted  to  300mM  and  filtered  through  a  0.2µm 
membrane.  The  clarified  supernatant  was  purified  via 
anti-FRA  affinity  chromatography,  using  1X  PBS  with 
2M NaCl, 1mM CHAPS, pH7.4 as wash buffer, followed 
by elution with 10mM MOPS, 3M MgCl2, 1mM CHAPS, 
pH6.8. Peak fractions were dialyzed extensively against 
1X  PBS,  pH7.4,  analyzed  for  purity  by  SDS-PAGE, 
quantitated by bicinchoninic acid (BCA) assay, aliquotted 
and stored at -80oC. 
Expression  and  purification  of  soluble  human 
FRA from recombinant CHO cells
A  human  FRA  sequence,  containing  a  human 
immunoglobin kappa leader sequence and a C-terminal 
6xhis epitope tag replacing the GPI attachment site, was 
used to prepare a Chinese hamster ovary (CHO) cell line 
stably expressing and secreting human FRA as described 
[39]. Transfected cells were grown in 25L wave bags. 
Supernatants  were  collected,  filtered  to  remove  debris, 
concentrated  10-fold  by  tangential  flow  filtration,  and 
then diafiltered into 50mM sodium phosphate, 300mM 
NaCl, 1mM imidazole, pH8.0. Samples were then loaded 
onto a pre-packed Talon IMAC column and fractionated 
using FPLC. Protein fractions were eluted using a linear 
gradient  of  5-100mM  imidazole  in  50mM  sodium 
phosphate,  300mM  NaCl,  pH8.0.  Peak  fractions  were 
dialyzed against 1X PBS, pH7.4, analyzed for purity by 
SDS-PAGE,  quantitated  by  BCA  assay,  aliquotted  and 
stored at -80oC.
Expression  and  purification  of  soluble  human 
FRA, FRB, FRD, and FRG from transiently-
transfected 293F cells
Recombinant vectors containing full length cDNAs 
encoding for human FRA, FRB, FRD, and FRG were all 
engineered  to  contain  a  human  immunoglobulin  kappa 
leader sequence and a C-terminal 6xhis epitope tag that 
replaced the GPI attachment site. Vectors were then used 
to transiently transfect 1L cultures of human 293F cells as 
previously described [39]. After 10 days of culture, cells 
were harvested and debris was removed by centrifugation. 
Supernatants containing secreted FR proteins were 
diafiltered and purified as described above.
Immunogen preparation
Purified  recombinant  FRA  (rFRA)  derived  from 
Sf9 cells was concentrated to 2mg/mL in PBS (pH7.4) 
using centrifugal filters (Amicon Ultra, 3kDa MWCO) 
and  quantified  using  a  BCA  assay  according  to  the 
manufacturer  (Thermo). To  generate  reduced/alkylated, 
denatured FRA (dFRA), a portion of the rFRA preparation 
was  diluted  1:1  in  8M  urea/PBS  to  generate  a  final 
concentration  of  1mg/mL  FRA  in  PBS  containing  4M 
urea. Dithiothreitol (DTT) solution (500mM in PBS) was 
added to a final concentration of 10mM. The solution was 
incubated at 65oC for 1hr, and cooled to room temperature 
(RT).  Next,  1M  iodoacetamide  solution  in  PBS  was 
added into the reduced folate receptor solution to a final Oncotarget 2011; 2:   1227 - 1243 1238 www.impactjournals.com/oncotarget
concentration of 10mM, and the reaction was kept in the 
dark at RT for 30min. The final reduced/alkylated FRA 
was dialyzed into PBS containing 4M urea, 10mM DTT 
and 10mM iodoacetamide and stored at -80oC until use.
Immunization, cell fusion and hybridoma cloning 
Five  eight-week  old  female  Balb/c  mice  were 
immunized  with  rFRA  or  dFRA  protein  as  follows. 
Initial  intraperitoneal  immunizations  administered  on 
day 0 comprised 50μg of rFRA or dFRA prepared as a 
1:1 (v:v) mix with complete Freund’s adjuvant (Rockland 
Immunochemicals, Inc., Gilbertsville, PA). Boosts (50μg 
immunogen  mixed  1:1  (v:v)  with  incomplete  Freund’s 
adjuvant;  Rockland  Immunochemicals  Inc.)  were 
administered intraperitoneally on day 14 and every 21 days 
thereafter. Test bleeds were collected on day 24 and every 
21 days thereafter and analyzed by direct enzyme-linked 
immunoassay (EIA) against rFRA (see below). Spleens 
were  harvested  from  animals  exhibiting  the  highest 
antigen-specific titers and hybridomas were prepared by 
electrofusion (Hybrimune™ Model CEEF-50B Waveform 
Generator; Cellectis, Romainville, France) of splenocytes 
with Sp2/0 Ag14 myeloma cells (ATTC, Rockville, MD). 
Hybridoma supernatants were rescreened by EIA against 
rFRA or recombinant mesothelin protein as a negative 
control,  to  identify  hybridomas  producing  anti-FRA 
antibodies.  Selected  parental  cell  lines  were  then  sub-
cloned by limiting dilution and re-assayed against rFRA 
by EIA. Isotyping of selected clones was performed using 
the Clonetyping System (SouthernBiotech, Birmingham, 
AL). 
Monoclonal  antibody  (mAb)  selection  –  Direct 
EIA
mAb selection was performed using a direct EIA 
technique.  Briefly,  96-well  plates  were  coated  with 
100µL/well  of  a  PBS  solution  containing  0.5µg/mL 
rFRA  overnight  at  4oC.  Wells  were  then  washed  and 
blocked with 3% (w/v) fish gel in PBS for 1hr at RT. 
Next,  100µL  of  a  3-fold  dilution  series  of  hybridoma 
culture supernatant was added to the wells and plates 
were incubated at RT for 1hr. After washing 3 times with 
PBS containing 0.2% (v/v) Tween-20 (PBST), 100µL of 
horseradish peroxidase-conjugated rabbit anti-mouse IgG 
(1:2500 dilution; Rockland Immunochemicals, Inc.) was 
added and plates were incubated for 30min at 37oC. After 
washing  with  PBST,  100µL  of  substrate  (TMBE-100; 
Rockland  Immunochemicals,  Inc.)  was  added  and  the 
reaction stopped after 30min by addition of 100µL of 1M 
HCl. Plates were read at 450nm on a Benchmark micro-
plate reader (BioRad, Concord, CA).
mAb  Selection  –  Immunohistochemistry  (IHC) 
on FFPE tissue secondary screen
Hybridoma cell culture supernatants were screened 
by  IHC  (see  below)  on  5µm  formalin  fixed  paraffin 
embedded  (FFPE)  sections  of  papillary  serous  ovarian 
carcinoma.  Preliminary  positivity  in  IHC  was  used  to 
aid  selection  of  hybridomas  for  further  analysis  and 
optimization in IHC.
mAb production and purification
Hybridoma cell lines were tested for mycoplasma 
using the mycoplasma PCR ELISA (Roche, Mannheim, 
Germany).  mAbs  were  produced  from  mycoplasma 
negative cells grown in 1L roller bottle cultures. After 
seeding  at  0.5x105  cells/mL,  cultures  were  grown  for 
14 days in serum free medium (Invitrogen) and 5% low 
IgG fetal bovine serum (Gibco). At termination, culture 
supernatants  were  concentrated  approximately  10-fold 
through  a  50kDa  filtration  membrane  (SpectrumLabs, 
Rancho  Dominguez,  CA)  and  mAbs  were  purified  by 
Protein  A  affinity  chromatography,  eluted  with  0.1M 
sodium citrate pH3.5 buffer, and subsequently dialyzed 
against  PBS  using  a  12-14kDa  membranous  tubing 
(SpectrumLabs, Rancho Dominguez CA), sterile filtered 
using  0.22μm  Express™PLUS  Stericups  (Millipore, 
Billerica MA), aliquotted and stored at -80oC.
Fluorescense Activated Cell Sorting (FACS) 
analysis
The specificity of the anti-human FRA mAbs was 
assessed by FACS analysis using stably transfected CHO 
cell lines, each expressing a different member of the folate 
receptor family. cDNAs encoding the full length FRA, 
FRB  or  FRD  homologs  were  cloned  into  a  eukaryotic 
expression  vector  and  transfected  into  CHO  cells  and 
selected for expression as previously described [39]. After 
establishment of stable FRA, FRB and FRD expressing 
CHO cells, cells were expanded and tested for FRA, FRB, 
and  FRD  expression  by  RNA  and  western  blot  using 
polyclonal antisera generated against each antigen. Stable 
cell lines were then used to study FR expression and as 
reagents to screen for FRA specific antibodies. For FACS, 
cells  were  harvested  in  PBS/EDTA,  washed,  and  re-
suspended in ice-cold growth media (RPMI supplemented 
with  10%  FBS).  Cells  were  incubated  for  1hr  on  ice 
with 1µg/mL of a mAb, washed and then incubated with 
FITC-conjugated  secondary  antibodies  [dilution  1:100] 
(Southern Biotech, Birmingham, AL). Prior to analysis, 
cells were labeled with 7-Amino-actinomycin D (7-AAD) 
(BD Biosciences, Franklin Lakes, NJ) for the exclusion 
of nonviable cells. Cells were analyzed on an EasyCyte Oncotarget 2011; 2:   1227 - 1243 1239 www.impactjournals.com/oncotarget
Flow  Cytometer  (Guava  Technologies,  Hayward,  CA). 
Data  is  presented  as  graphical  representation  of  mean 
fluorescence intensity (MFI) of 7-AAD negative, viable 
cells.  For  FACS  competition  studies,  cells  were  first 
incubated with one antibody and then washed and re-
incubated  similarly  with  a  second  antibody  and  then 
analyzed on the EasyFlow Cytometer as described above. 
Western Blot Analysis of Cell Lysates
CHOK1  transfected  cells  stably  expressing  GPI-
linked  human  FRA,  FRB  or  FRD  respectively  were 
lysed  in  1.1%  OBG  buffer  (50mM  Tris-HCl,  pH7.5, 
150mM NaCl, 1.1% OBG) supplemented with Complete 
Mini  Protease  Inhibitor  Cocktail  (Roche  Diagnostics, 
Indianapolis, IN) and PMSF (100nM), and placed on ice 
for 15min. Lysates were pre-cleared by centrifugation at 
13,000rpm for 15min to remove debris. Equal amounts of 
protein (20µg) were boiled for 10 min in NuPAGE LDS 
sample  buffer  (Invitrogen)  with  5%  β-mercaptoethanol 
(BME) and 40mM DTT for reducing gels or without for 
non-reduced  gels.  Proteins  were  separated  using  SDS-
polyacrylamide  gel  electrophoresis  (SDS-PAGE)  on  a 
4-12% Bis-Tris gel (Invitrogen) and electroblotted onto 
PVDF  membrane.  After  transfer,  the  membrane  was 
blocked in PBST and 5% non-fat milk for 1h at RT and 
then  washed  twice  with  PBST.  Immunoblotting  was 
conducted  using  purified  anti-FRA  mouse  mAbs  (1μg/
mL),  detected  with  a  goat-anti-mouse  HRP-conjugated 
antibody  and  visualized  using  SuperSignal  West  Pico 
chemiluminescent substrate (Pierce, Rockford, IL). The 
LK26 antibody was used as a positive control for FRA 
detection. Luminescence was visualized using the Omega 
12iC molecular imaging system (Ultra-Lum, Claremont, 
CA) with image analysis performed using UltraQuant 6.0 
software (Ultra-Lum). 
Western blotting using purified FR isoforms
0.5µg of purified human FRA, FRB, FRD, and FRG 
produced as described above were incubated in 1X SDS-
PAGE sample loading buffer (Invitrogen) with or without 
20mM DTT, boiled for 10min, and electrophoresed on 
4-12% gradient SDS-PAGE gels. Protein was transferred 
to PVDF membrane and blots probed as described above. 
Gels  were  run  using  Benchmark™  prestained  protein 
ladder  (Novex®).  Gels  using  purified  recombinant  FR 
proteins were also visualized via silverstaining to ensure 
equal amounts of protein were loaded.
Immunohistochemistry
Immunohistochemical (IHC) testing to detect FRA 
was performed using formalin fixed paraffin embedded 
(FFPE) or fresh frozen (FF) tissues. For FFPE specimens, 
IHC  was  performed  using  a  MACH4  Universal  HRP-
Polymer Detection Kit (Biocare Medical, Concord, CA). 
FFPE specimens were sectioned at 5µm on positively-
charged glass slides and heated for approximately 60min 
at 60°C. Slides were deparaffinized in 3 sequential baths 
of xylene for 3min each, transferred to three sequential 
baths of 100% alcohol for 3min each, followed by three 
sequential baths of 95% alcohol for 3min each and then 
rinsed for 5min in deionized (DI) water. Slides were then 
pretreated in Diva heat-induced epitope retrieval solution 
(Biocare Medical) diluted 1:10 in DI water and placed 
inside  a  pressurized  decloaking  chamber  already  filled 
with  500mL  of  DI  water.  For  antigen  retrieval,  slides 
were incubated for 15min inside the decloaking chamber 
in which pressurized incubation reaches a maximum of 
125C at 16 PSI for 30sec and then cooled for 15min down 
to 95°C. After cooling to RT, slides were washed in 3 
sequential baths of Tris Buffered Saline/0.1% Tween-20 
wash buffer (TBST) for 3min each and subsequently placed 
into Peroxidase-1 (Biocare Medical) blocking solution for 
5min at RT. After washing in TBST as above, Background 
Sniper (Biocare Medical) serum-free universal blocking 
reagent was applied for 10min at RT. Slides were then 
incubated with either individual anti-FRA cell culture 
supernatants (hybridoma secondary screening; undiluted 
culture  supernatant)  or  purified  mAbs  at  2.5µg/mL 
diluted in Antibody Diluent (Dako) or Universal Negative 
Control  [mouse  ready-to-use  negative  control  antibody 
(Dako, for negative isotype tissue)] for 60min at RT. After 
washing,  slides  were  incubated  with  MACH4  Mouse 
Probe Primary Antibody Enhancer for 15min, followed 
by  Polymer-HRP  reagent  for  20min,  developed  with  a 
3,3′-diaminobenzidine tetrahydrochloride (DAB) solution 
(Dako)  for  5min  and  counterstained  with  hematoxylin 
(Dako)  for  2min,  all  incubations  being  performed  at 
RT. For IHC on fresh frozen (FF) sections, tissues were 
harvested and snap frozen in liquid nitrogen and stored 
at  -80°C  until  used.  FF  tissue  samples  were  sectioned 
at 5µm onto positively-charged glass slides at 4°C and 
subsequently stained using the methods described above, 
excluding the deparaffinization steps. 
Surface Plasmon Resonance
All surface plasmon resonance (SPR) experiments 
were  performed  at  25°C  using  a  BIAcore  T100  with 
research grade CM5 chips (GE Healthcare). Following 
the  instructions  provided  by  the  manufacturer,  anti-
mouse IgG provided in the mouse antibody capture kit 
(GE  Healthcare)  was  immobilized  by  amide  coupling 
to  CM5  sensor  chips.  Murine  anti-human  FRA  mAbs 
were  captured  on  individual  flow  cells  per  binding 
cycle, while the fourth flow cell was used as a reference. 
Binding experiments were performed with HBS-P (GE 
Healthcare) as running buffer and at a flow rate of 30µL/Oncotarget 2011; 2:   1227 - 1243 1240 www.impactjournals.com/oncotarget
min. Each mAb sample (0.5µg/mL) was injected for 3min 
to capture the antibody. Various concentrations of purified 
rhFRA (1nM - 30nM) were then injected over the anti-
FRA flow cells and reference surfaces for 3min to record 
binding sensograms using a single-cycle kinetics method. 
The  dissociation  profile  was  monitored  for  25min.  In 
between bindings, the surface was regenerated with a 30µl 
injection of 10mM glycine (pH1.7). The sensograms were 
processed  and  fitted  to  a  1:1  Langmuir  binding  model 
using BIAcore T100 evaluation software (version 2.0.1).
Epitope binning by biolayer inferometry
Antibody epitopes were analyzed to localize FRA 
binding  by  first  epitope  binning  techniques  [31]  and 
subsequently  further  refined  using  hydrogen-deuterium 
(H/D) exchange mapping (below) [32]. Epitope binning 
was  performed at  30°C  using  an  Octet QK  (ForteBio) 
with PBS containing 0.005% Tween20 (PBST) as buffer. 
Purified  human  rFRA  was  biotinylated  with  EZ-Link 
Sulfo-NHS-LC-Biotin  following  the  protocol  provided 
by the manufacturer (Thermo Scientific). Briefly, a 20-
fold  molar  excess  of  biotin  was  incubated  with  rFRA 
for 40min at room temperature. The biotinylated rFRA 
was  then  dialyzed  extensively  against  PBS  at  4°C. 
Streptavidin-coated biosensors (SA sensors, ForteBio) 
were pre-wet for 10min in PBST containing 0.1% BSA, 
immediately before use. Biotinylated rFRA was coupled 
onto  SA  sensors  by  dipping  the  sensors  in  microplate 
wells containing 220µl of the biotinylated FRA (3µg/ml) 
for 10min at an agitation speed of 300rpm. A new baseline 
was established for each sensor in PBST buffer for 3min. 
The FRA-coupled biosensors were dipped into a column 
of wells containing a primary saturating anti-FRA mAb 
(400nM)  for  10min  at  an  agitation  speed  of  1500rpm. 
Then the biosensors were moved into a column of wells 
containing six different secondary competing anti-FRA 
mAbs (400nM, 10min). Two wells containing PBST and 
the primary anti-FRA mAb, respectively, were included in 
the column for referencing purposes. The dissociation of 
anti-FRA mAbs was monitored for 5min. 
Epitope mapping by hydrogen/deuterium 
exchange
Immobilization of antibody
Purified  monoclonal  antibody  was  immobilized 
on POROS 20 AL media (Applied Biosystems) per the 
manufacturer’s instructions. Briefly, 100mgs of POROSAL 
and  4mg  sodium  cyanoborohydride  (NaCNBH3) were 
added  to  1mg  of  mAb. After  addition  of  0.5mL  2.8M 
sodium sulfate (Na2SO4), the reaction mixture was shaken 
at RT overnight. The resin was washed with PBS and then 
shaken with 2mL of PBS containing 1M ethanolamine and 
8mg/mL of NaCNBH3 at RT for 2h to cap the unreacted 
aldehyde groups. The capped resin was washed with PBS 
and resuspended in PBS. 
On-Exchange of rFRA in Solution 
In  H/D  exchange  studies,  “on”  reactions  refer 
to  those  in  which  protein(s)  are  exposed  to  deuterium 
solutions,  resulting  in  the  exchange  of  hydrogen  for 
deuterium. “Off” reactions, conversely, refer to those in 
which deuterated proteins are exposed to non-deuterated 
solutions,  resulting  in  the  exchange  of  deuterium  with 
hydrogen.  On-exchange  experiments  with  human 
rFRA  were  performed  in  order  to  assess  the  dynamic 
properties of the protein in solution and identify regions 
of  fast  exchange  (solvent-exposed)  and  slow-exchange 
(interior regions). ‘On-solution’ (on-exchange in solution) 
reactions were initiated by diluting 5µL of 1mg/mL rFRA 
with 35µL of deuterated buffer (1X PBS, 87% D2O). The 
reaction mixture was incubated at 23°C for varying times 
(30, 100, 300, 1000, and 3000s). Fully deuterated sample 
was prepared by mixing 5µL of a 1mg/mL rFRA with 
35µL of 100mM TCEP in D2O and incubating at 60°C 
for 3h. 20μL of 2M urea, 1M TCEP, pH3.0 was added 
to the exchange reactions to quench the deuteration. The 
mixture was subjected to papain digestion, LC-MS/MS, 
and data analysis (see below).
Principle of epitope mapping by H/D exchange using 
immobilized monoclonal antibody
In the labeling experiment, rFRA is on-exchanged in 
solution for a predetermined time and then off-exchanged 
in the antibody column for the same duration (Figure 4). 
The anti-FRA epitope becomes deuterated during the on-
exchange as it is exposed to the solvent and may retain 
deuterium during the off-exchange as it may be protected 
by the anti-FRA antibody. Conversely, regions that are not 
affected by antibody binding may be deuterated during 
the on-exchange but will lose deuterium during the off-
exchange. More information about H/D epitope mapping 
can be found at www.exsar.com. 
‘On-solution/off-column’ analysis
‘On-solution’  (on-exchange  in  solution)  reactions 
were initiated by diluting 5µL of 1mg/mL rFRA with 35µL 
of deuterated buffer (1X PBS, 87% D2O). The reaction 
mixture was incubated at 3°C for varying times (150, 500, 
1500, and 5000s). The on-exchanged solution was loaded 
onto the antibody column that was pre-equilibrated with 
deuterated buffer, and then washed once with deuterated 
buffer. ‘Off-column’ (off-exchange in column) reactions 
were  initiated  by  washing  the  column  with  200µL  of 
chilled 1X PBS. ‘Off-column’ reactions continued for one 
half of the preceding on-exchange duration (75, 250, 750, 
and 2500s). The introduction of 140µL of 0.8% formic 
acid quenched the exchange reactions and eluted out the 
FRA  from  the  antibody  column. The  last  40µL  of  the 
eluent was collected and added to 20µL of 2M GuHCl, Oncotarget 2011; 2:   1227 - 1243 1241 www.impactjournals.com/oncotarget
1M TCEP, pH 3.0. The mixture was subjected to papain 
digestion, LC-MS/MS, and data analysis (see below).
‘On-column/off-column’ analysis
The column from above was regenerated by washing 
twice with 250µL 0.8% formic acid, then equilibrated twice 
with 250µL of ice chilled PBS. 5µL of 1mg/mL rFRA was 
diluted with 35µL of ice chilled 1X PBS (0% D2O). The 
reaction mixture was incubated at 3°C for varying times 
(150, 500, 1500, and 5000s). The solution was loaded 
onto the antibody column and then washed once with 1X 
PBS.  ‘On-column’  reactions  were  initiated  by  washing 
the column with 100µL of ice chilled deuterated buffer 
(1X PBS, 87% D2O). ‘On-column’ reactions continued for 
75, 250, 750, and 2500s. Subsequent off-column, elution, 
papain  digestion,  LC-MS/MS,  and  data  analysis  were 
identical to on-solution/off-column analysis. 
Papain digestion, LC-MS/MS, and data analysis
For papain digestion, samples were passed over an 
immobilized pepsin column at 200 µL/min in buffer A 
(0.05% TFA in H2O). Peptic fragments were loaded onto 
a reversed-phase trap column and desalted with buffer A 
at 200µL/min for 3min. Peptic peptides were separated 
by a C18 column with a linear gradient of 13% to 40% 
buffer B (95% acetonitrile, 5% H2O, 0.0025% TFA) in 
buffer A  for  23min.  Peptic  peptides  were  analyzed  by 
mass spectrometry using a Thermo Finnigan LCQTM mass 
spectrometer  (Thermo  Fisher,  San  Jose,  CA)  with  the 
capillary temperature set at 175°C in MS1:Profile mode. 
Deuteration level of each peptide analyzed was analyzed 
as described in Coales et al [32].
Refinement  of  MORAb-003  epitope  by  alanine 
scanning mutagenesis
Mutant soluble human FRA constructs were designed 
such that adjacent pairs of amino acids in the MORAb-
003-protected region of FRA identified by H/D exchange 
mapping (amino acids 45-57) were mutated to alanine, 
with  the  exception  of  Ala50,  which  was  changed  to 
glycine. Mutant FRA constructs overlapped by one amino 
acid, generating a total of 12 mutant FRA constructs. These 
mutant FRA constructs, along with wild-type FRA, were 
transiently-transfected  into  293F  cells  and  supernatant 
was  collected,  centrifuged,  and  filtered.  For  BIAcore 
analysis of mutants, a CM5 chip was prepared having 
12,000 RU PentaHis anti-his tag antibody immobilized 
on all four flow cells (Qiagen) using standard EDC/NHS 
chemistry on a BIAcore 3000 instrument. Wild-type and 
mutant FRA supernatants were diluted 1:10 in HBS-EP 
buffer and were captured on flow cells 2-4 of the PentaHis 
chip at RU levels of 100-200 RU. Flow cell 1 was used as 
a reference flow cell. MORAb-003 (0nM-30nM in HBS-
EP buffer) was injected over all four flow cells. Data was 
double-referenced, and kinetic constants were determined 
using BIAevaluations.
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